Spotlight on Aurora Cannabis

Like a deflating tire, the North American cannabis index has been slowly sinking since mid-March, testing investors’ patience and enthusiasm for the sector. And just as a rising tide lifts all boats, a sinking tide can pull all ships down with it. In this case, it’s Aurora Cannabis (NYSE:ACB) stock that’s being pulled under by a cannabis market that seems to be taking a breather.

That tide will likely rise again as Canada prepares to legalize CBD edibles, beverages, extracts and topicals later this year. For Aurora in particular, however, there are three company-specific catalysts that make it especially attractive at the current valuation.

Sure, Aurora is the second-largest Canadian cultivator by market cap ($10.1 billion, to be exact), but there’s more to Aurora than its considerable presence in the Great White North. Too many investors ignore burgeoning cannabis markets abroad, but Aurora is an early mover in this field with multiple acquisitions and joint ventures.

Read the full article at Investor Place.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down